Allergic fungal airway disease

Journal of Investigational Allergology and Clinical Immunology

Volumn 26, Issue 6, 2016, Pages 344-354

  Rick, E M ^a   Woolnough, K ^a   Pashley, C H ^a   Wardlaw, Andrew J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

ABPA; Allergic fungal airway disease (AFAD); Allergic fungal rhinosinusitis (AFRS); Asthma; Diagnosis; Immune responses; SAFS; Thermotolerant fungi; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; INTERLEUKIN 4; ITRACONAZOLE; VORICONAZOLE; ANTIASTHMATIC AGENT; ANTIFUNGAL AGENT; FUNGUS ANTIGEN;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ALLERGIC FUNGAL AIRWAY DISEASE; ALLERGIC RHINITIS; ALTERNARIA; ANAMNESIS; ANTIFUNGAL THERAPY; ANTIGENICITY; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASTHMA; ATOPIC DERMATITIS; BODY TEMPERATURE; CANDIDA; CLADOSPORIUM; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); EOSINOPHILIA; FUNGAL SINUSITIS; FUNGUS; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; LUNG FIBROSIS; LUNG INJURY; NOSE POLYP; PEAK EXPIRATORY FLOW; PENICILLIUM; PENICILLIUM CHRYSOGENUM; PENICILLIUM CITRINUM; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; RHINORRHEA; RHINOSINUSITIS; CLASSIFICATION; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LUNG; LUNG DISEASES, FUNGAL; MICROBIOLOGY; PROCEDURES; PROGNOSIS; RESPIRATORY HYPERSENSITIVITY;

ANTI-ASTHMATIC AGENTS; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; FUNGI; HUMANS; IMMUNOTHERAPY; LUNG; LUNG DISEASES, FUNGAL; PROGNOSIS; RESPIRATORY HYPERSENSITIVITY;

EID: 85006699895     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: 10.18176/jiaci.0122     Document Type: Review

References (129)

1. Kirk PM, Cannon PF, Minter DW, Stalpers JA. Ainsworth and Bisby’s dictionary of the Fungi. 10th edition ed. Wallingford, UK: CAB International 2008.
2. Hawksworth DL. The magnitude of fungal diversity: the 1.5 million species estimate revisited. Mycol Res. 2001;105:1422-32.
3. Hawksworth DL. Global species numbers of fungi: are tropical studies and molecular approaches contributing to a more robust estimate? Biodivers Conserv. 2012;21(9):2425-33.
4. James TY, Kauff F, Schoch CL, Matheny PB, Hofstetter V, Cox CJ, Celio G, Gueidan C, Fraker E, Miadlikowska J, Lumbsch HT, Rauhut A, Reeb V, Arnold AE, Amtoft A, Stajich JE, Hosaka K, Sung GH, Johnson D, O’Rourke B, Crockett M, Binder M, Curtis JM, Slot JC, Wang Z, Wilson AW, Schussler A, Longcore JE, O’Donnell K, Mozley-Standridge S, Porter D, Letcher PM, Powell MJ, Taylor JW, White MM, Griffith GW, Davies DR, Humber RA, Morton JB, Sugiyama J, Rossman AY, Rogers JD, Pfister DH, Hewitt D, Hansen K, Hambleton S, Shoemaker RA, Kohlmeyer J, Volkmann-Kohlmeyer B, Spotts RA, Serdani M, Crous PW, Hughes KW, Matsuura K, Langer E, Langer G, Untereiner WA, Lucking R, Budel B, Geiser DM, Aptroot A, Diederich P, Schmitt I, Schultz M, Yahr R, Hibbett DS, Lutzoni F, McLaughlin DJ, Spatafora JW, Vilgalys R. Reconstructing the early evolution of Fungi using a six-gene phylogeny. Nature. 2006;443(7113):818-22.
5. Hardin BD, Kelman BJ, Saxon A. Adverse human health effects associated with molds in the indoor environment. Int J Occup Environ Med. 2003;45(5):470-78.
6. Hawksworth DL. The fungal dimension of biodiversity-magnitude, significance, and conservation. Mycol Res. 1991;95:641-55.
7. Woolnough K, Fairs A, Pashley CH, Wardlaw AJ. Allergic fungal airway disease: pathophysiologic and diagnostic considerations. Curr Opin Pulm Med. 2015;21(1):39-47.
8. Heitman J. Microbial Pathogens in the Fungal Kingdom. Fungal Biol Rev. 2011;25(1):48-60.
9. Horner WE, Helbling A, Salvaggio JE, Lehrer SB. Fungal Allergens. Clin Microbiol Rev. 1995;8(2):161-79.
10. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, Moss RB, Niven RM, Pashley CH, Slavin RG, Vijay HM, Wardlaw AJ. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280-91.
11. Luong A, Marple BF. Update on Allergic Fungal Rhinosinusitis. Curr. Fungal Infect. Rep. 2007;1(1):12-18.
12. AllergyUK. Indoor allergy week 2011: The rise of ‘home fever’. 2011.
13. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004;34(4):520-26.
14. Pashley CH, Fairs A, Free RC, Wardlaw AJ. DNA analysis of outdoor air reveals a high degree of fungal diversity, temporal variability, and genera not seen by spore morphology. Fungal Biol. 2012;116(2):214-24.
15. Fairs A, Wardlaw AJ, Thompson JR, Pashley CH. Guidelines on ambient intramural airborne fungal spores. J Investig Allergol Clin Immunol. 2010;20(6):490-98.
16. Burge HA. An update on pollen and fungal spore aerobiology. J Allergy Clin Immunol. 2002;110(4):544-52.
17. Green BJ, Sercombe JK, Tovey ER. Fungal fragments and undocumented conidia function as new aeroallergen sources. J Allergy Clin Immunol. 2005;115(5):1043-8.
18. Green BJ, Tovey ER, Sercombe JK, Blachere FM, Beezhold DH, Schmechel D. Airborne fungal fragments and allergenicity. Med Mycol. 2006;44:S245-S55.
19. Cho SH, Seo SC, Schmechel D, Grinshpun SA, Reponen T. Aerodynamic characteristics and respiratory deposition of fungal fragments. Atmos Environ. 2005;39(30):5454-65.
20. Romani L. Immunity to fungal infections. Nat Rev Immunol. 2011;11(4):275-88.
21. Green BJ, Mitakakis TZ, Tovey ER. Allergen detection from 11 fungal species before and after germination. J Allergy Clin Immunol. 2003;111(2):285-9.
22. Aimanianda V, Bayry J, Bozza S, Kniemeyer O, Perruccio K, Elluru SR, Clavaud C, Paris S, Brakhage AA, Kaveri SV, Romani L, Latge JP. Surface hydrophobin prevents immune recognition of airborne fungal spores. Nature. 2009;460(7259):1117-U79.
23. Crameri R, Garbani M, Rhyner C, Huitema C. Fungi: the neglected allergenic sources. Allergy. 2014;69(2):176-85.
24. Simon-Nobbe B, Denk U, Poll V, Rid R, Breitenbach M. The spectrum of fungal allergy. Int Arch Allergy Immunol. 2008;145(1):58-86.
25. Borghi M, Renga G, Puccetti M, Oikonomou V, Palmieri M, Galosi C, Bartoli A, Romani L. Antifungal Th immunity: growing up in family. Front Immunol. 2014;5:1-8.
26. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-54.
27. Rajan TV. The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol. 2003;24(7): 376-9.
28. Wardlaw AJ, Woolnough K, Pashley CH. Lassoing a chimera: the semantics of allergic fungal airway disease. Clin Exp Allergy. 2015;45(12):1746-9.
29. Faergemann J. Atopic dermatitis and fungi. Clin Microbiol Rev. 2002;15(4):545-63.
30. Twaroch TE, Curin M, Valenta R, Swoboda I. Mold Allergens in Respiratory Allergy: From Structure to Therapy. Allergy Asthma Immunol Res. 2015;7(3):205-20.
31. Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Del Giacco S, Delhaes L, Sergejeva S. Fungal allergy in asthmastate of the art and research needs. Clin Transl Allergy. 2014;4:14.
32. O’Driscoll BR, Powell G, Chew F, Niven RM, Miles JF, Vyas A, Denning DW. Comparison of skin prick tests with specific serum immunoglobin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy. 2009;39:1677-83.
33. Niemeijer NR, de Monchy JG. Age-dependency of sensitization to aero-allergens in asthmatics. Allergy. 1992;47(4 Pt 2):431-5.
34. Bartra J, Belmonte J, Torres-Rodriguez JM, Cistero-Bahima A. Sensitization to Alternaria in patients with respiratory allergy. Front Biosci (Landmark Ed). 2009;14:3372-79.
35. Bousquet PJ, Hooper R, Kogevinas M, Jarvis D, Burney P. Number of allergens to be tested to assess allergenic sensitization in epidemiologic studies: results of the European Community Respiratory Health Survey I. Clin Exp Allergy. 2007;37(5):780-7.
36. Agarwal R. Allergic Bronchopulmonary Aspergillosis. Chest. 2009;135(3):805-26.
37. Chowdhary A, Agarwal K, Kathuria S, Gaur SN, Randhawa HS, Meis JF. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol. 2014;40(1):30-48.
38. Crameri R, Zeller S, Glaser AG, Vilhelmsson M, Rhyner C. Cross-reactivity among fungal allergens: a clinically relevant phenomenon? Mycoses. 2009;52(2):99-106.
39. Bowyer P, Fraczek M, Denning DW. Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues. BMC Genomics. 2006;7(1):251.
40. Vacher G, Niculita-Hirzel H, Roger T. Immune responses to airborne fungi and non-invasive airway diseases. Semin Immunopathol. 2014;37(2):83-96
41. Migueres M, Davila I, Frati F, Azpeitia A, Jeanpetit Y, Lheritier-Barrand M, Incorvaia C, Ciprandi G. Types of sensitization to aeroallergens: definitions, prevalences and impact on the diagnosis and treatment of allergic respiratory disease. Clin Transl Allergy. 2014;4:16.
42. Mari A, Schneider P, Wally V, Breitenbach M, Simon-Nobbe B. Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts. Clin Exp Allergy. 2003;33(10):1429-38.
43. Crameri R. The problem of cross-reactivity in the diagnosis of fungal allergy. Clin Exp Allergy. 2011;41(3):302-4.
44. Crameri R. Immunoglobulin E-binding autoantigens: biochemical characterization and clinical relevance. Clin Exp Allergy. 2012;42(3):343-51.
45. Hemmann S, Blaser K, Crameri R. Allergens of Aspergillus fumigatus and Candida boidinii share IgE-binding epitopes. Am J Respir Crit Care Med. 1997;156(6):1956-62.
46. Soeria-Atmadja D, Onell A, Borga A. IgE sensitization to fungi mirrors fungal phylogenetic systematics. J Allergy Clin Immunol. 2010;125(6):1379-86.
47. Shen HD, Lin WL, Tsai JJ, Liaw SF, Han SH. Allergenic components in three different species of Penicillium: crossreactivity among major allergens. Clin Exp Allergy. 1996;26(4):444-51.
48. Cantani A, Ciaschi V. Epidemiology of Alternaria alternata allergy: a prospective study in 6840 Italian asthmatic children. Eur Rev Med Pharmacol Sci. 2004;8(6):289-94.
49. Chauhan B, Santiago L, Hutcheson PS, Schwartz HJ, Spitznagel E, Castro M, Slavin RG. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2000;106(4):723-9.
50. Chauhan B, Santiago L, Kirschmann DA, Hauptfeld V, Knutsen AP, Hutcheson PS, Woulfe SL, Slavin RG, Schwartz HJ, Bellone CJ. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. J Immunol. 1997;159(8):4072-6.
51. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009;13(8):936-44.
52. Esch RE. Manufacturing and standardizing fungal allergen products. J Allergy Clin Immunol. 2004;113(2):210-5.
53. Liang KL, Su MC, Jiang RS. Comparison of the skin test and ImmunoCAP system in the evaluation of mold allergy. J Chin Med Assoc. 2006;69(1):3-6.
54. Silvestri M, Rossi GA, Cozzani S, Pulvirenti G, Fasce L. Agedependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. Ann Allergy Asthma Immunol. 1999;83(4):335-40.
55. Malling HJ. Reproducibility of skin sensitivity using a quantitative skin prick test. Allergy. 1985;40(6):400-4.
56. Thomsen GF, Schlunssen V, Skadhauge LR, Malling TH, Sherson DL, Omland O, Sigsgaard T. Are allergen batch differences and the use of double skin prick test important? BMC Pulm Med. 2015;15:33.
57. Buzina W, Braun H, Freudenschuss K, Lackner A, Habermann W, Stammberger H. Fungal biodiversity-as found in nasal mucus. Med Mycol. 2003;41(2):149-61.
58. Bakhshaee M, Fereidouni M, Mohajer MN, Majidi MR, Azad FJ, Moghiman T. The prevalence of allergic fungal rhinosinusitis in sinonasal polyposis. Eur Arch Otorhinolaryngol. 2013;270(12):3095-8.
59. Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies. Laryngoscope. 2001;111(6):1006-19.
60. Manning SC, Holman M. Further evidence for allergic pathophysiology in allergic fungal sinusitis. Laryngoscope. 1998;108(10):1485-96.
61. Montone KT, Livolsi VA, Feldman MD, Palmer J, Chiu AG, Lanza DC, Kennedy DW, Loevner LA, Nachamkin I. Fungal rhinosinusitis: a retrospective microbiologic and pathologic review of 400 patients at a single university medical center. Int J Otolaryngol. 2012;2012:684835.
62. Safirstein BH. Allergic bronchopulmonary aspergillosis with obstruction of the upper respiratory tract. Chest. 1976;70(6):788-90.
63. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110(5):685-92.
64. Shah A, Panchal N, Agarwal AK. Concomitant allergic bronchopulmonary aspergillosis and allergic Aspergillus sinusitis: a review of an uncommon association. Clin Exp Allergy. 2001;31(12):1896-905.
65. Ryan MW, Clark CM. Allergic Fungal Rhinosinusitis and the unified airway: the role of antifungal therapy in AFRS. Curr Allergy Asthma Rep. 2015;15(12):75.
66. Callejas CA, Douglas RG. Fungal rhinosinusitis: what every allergist should know. Clin Exp Allergy. 2013;43(8):835-49.
67. Glass D, Amedee RG. Allergic fungal rhinosinusitis: a review. Ochsner J. 2011;11(3):271-5.
68. Ferguson BJ. Eosinophilic mucin rhinosinusitis: a distinct clinicopathological entity. Laryngoscope. 2000;110(5 Pt 1):799-813.
69. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-78.
70. Niven R. Asthma and mould allergy-Does it matter? Med Mycol. 2006;44:S257-S59.
71. Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy. 2009;39(11):1652-8.
72. Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy. 2010;40(1):62-7.
73. Wardlaw AJ, Brightling CE, Green R, Woltmann G, Bradding P, Pavord ID. New insights into the relationship between airway inflammation and asthma. Clin Sci. 2002;103(2):201-11.
74. Kay AB. Pathology of mild, severe, and fatal asthma. Am J Respir Crit Care Med. 1996;154(2):S66-S9.
75. Munakata M. Airway remodeling and airway smooth muscle in asthma. Allergol Int. 2006;55:235-43.
76. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol. 2012;10(7):459-71.
77. Lotvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, Lemanske RF, Wardlaw AJ, Wenzel SE, Greenberger PA. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355-60.
78. Atkinson RW, Strachan DP, Anderson HR, Hajat S, Emberlin J. Temporal associations between daily counts of fungal spores and asthma exacerbations. Int J Occup Environ Med. 2006;63(9):580-90.
79. Newson R, Strachan D, Corden J, Millington W. Fungal and other spore counts as predictors of admissions for asthma in the Trent region. Int J Occup Environ Med. 2000;57:786-92.
80. Dales RE, Cakmak S, Judek S, Dann T, Coates F, Brook JR, Burnett RT. The role of fungal spores in thunderstorm asthma. Chest. 2003;123(3):745-50.
81. Pulimood TB, Corden JM, Bryden C, Sharpies L, Nasser SM. Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol. 2007;120:610-7.
82. Delfino RJ, Zeiger RS, Seltzer JM, Street DH, Matteucci RM, Anderson PR, Koutrakis P. The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect. 1997;105(6):622-35.
83. Garrett MH, Rayment PR, Hooper MA, Abramson MJ, Hooper BM. Indoor airborne fungal spores, house dampness and associations with environmental factors and respiratory health in children. Clin Exp Allergy. 1998;28(4):459-67.
84. Andriessen JW, Brunekreef B, Roemer W. Home dampness and respiratory health status in European children. Clin Exp Allergy. 1998;28(10):1191-200.
85. ten Have WHo, van den Berg NJ, van der Palen J, van Aalderen WMC, Bindels PJE. Residential exposure to mould and dampness is associated with adverse respiratory health. Clin Exp Allergy. 2007;37(12):1827-32.
86. Meng J, Barnes CS, Rosenwasser LJ, Childrens Mercy Ctr Environm H. Identity of the fungal species present in the homes of asthmatic children. Clin Exp Allergy. 2012;42(10):1448-58.
87. Reponen T, Lockey J, Bernstein DI, Vesper SJ, Levin L, Hershey GKK, Zheng S, Ryan P, Grinshpun SA, Villareal M, LeMasters G. Infant origins of childhood asthma associated with specific molds. J Allergy Clin Immunol. 2012;130(3):639-44.
88. Reponen T, Vesper S, Levin L, Johansson E, Ryan P, Burkle J, Grinshpun SA, Zheng S, Bernstein DI, Lockey J, Villareal M, Hershey GKK, LeMasters G. High environmental relative moldiness index during infancy as a predictor of asthma at 7 years of age. Ann Allergy Asthma Immunol. 2011;107(2):120-6.
89. Park J-H, Cox-Ganser JM, Kreiss K, White SK, Rao CY. Hydrophilic fungi and ergosterol associated with respiratory illness in a water-damaged building. Environ Health Perspect. 2008;116(1):45-50.
90. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy. 2000;55(5):501-4.
91. O’Hollaren MT, Yunginger JW, Offord KP, Somers MJ, Oconnell EJ, Ballard DJ, Sachs MI. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in youngpatients with asthma. N Engl J Med. 1991;324(6):359-63.
92. Jaakkola MS, Ieromnimon A, Jaakkola JJK. Are atopy and specific IgE to mites and molds important for adult asthma? J Allergy Clin Immunol. 2006;117(3):642-8.
93. Piipari R, Keskinen H. Agents causing occupational asthma in Finland in 1986-2002: Cow epithelium bypassed by moulds from moisture-damaged buildings. Clin Exp Allergy. 2005;35(12):1632-7.
94. McDonald JC, Keynes HL, Meredith SK. Reported incidence of occupational asthma in the United Kingdom, 1989-97. Int J Occup Environ Med. 2000;57(12):823-9.
95. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.
96. O’Driscoll BR, Hopkinson LC, Denning DW. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med. 2005;5:4.
97. Vicencio AG, Santiago MT, Tsirilakis K, Stone A, Worgall S, Foley EA, Bush D, Goldman DL. Fungal sensitization in childhood persistent asthma is associated with disease severity. Pediatr Pulmonol. 2014;49(1):8-14.
98. Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006;27(3):615-26.
99. Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy. 2011;66(5):679-85.
100. Fairs A, Agbetile J, Hargadon B, Bourne M, Monteiro WR, Brightling CE, Bradding P, Green RH, Mutalithas K, Desai D, Pavord ID, Wardlaw AJ, Pashley CH. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med. 2010;182(11):1362-8.
101. Agbetile J, Fairs A, Desai D, Hargadon B, Bourne M, Mutalithas K, Edwards RE, Morley JP, Monteiro WR, Kulkarni NS, Green RH, Pavord ID, Bradding P, Brightling CE, Wardlaw AJ, Pashley CH. Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1. Clin Exp Allergy. 2012;42(5):782-91.
102. Tillie-Leblond L, Tonnel A-B. Allergic bronchopulmonary aspergillosis. Allergy. 2005;60:1004-13.
103. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013;51(4):361-70.
104. Hinson KFW, Moon AJ, Plummer NS. Bronchopulmonary aspergillosis-a review and a report of 8 new cases. Thorax. 1952;7(4):317-33.
105. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R, Denning DW, Isham ACA. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850-73.
106. Woolnough KF, Richardson M, Newby C, Craner M, Bourne M, Monteiro W, Siddiqui S, Bradding P, Pashley CH, Wardlaw AJ. The relationship between biomarkers of fungal allergy and lung damage in asthma. Clin Exp Allergy. 2016.
107. Gravesen S. Fungi as a cause of allergic disease. Allergy. 1979;34(3):135-54.
108. Sudakin DL. Toxigenic fungi in a water-damaged building: an intervention study. Am J Ind Med. 1998;34(2):183-90.
109. Burr ML, Matthews IP, Arthur RA, Watson HL, Gregory CJ, Dunstan FDJ, Palmer SR. Effects on patients with asthma of eradicating visible indoor mould: a randomised controlled trial. Thorax. 2007;62(9):767-72.
110. Rudblad S, Andersson K, Stridh G, Bodin L, Juto JE. Slowly decreasing mucosal hyperreactivity years after working in a school with moisture problems. Indoor Air. 2002;12(2):138-44.
111. Shortt N, Rugkasa J. “The walls were so damp and cold” fuel poverty and ill health in Northern Ireland: results from a housing intervention. Health Place. 2007;13(1):99-110.
112. Ebbehoj NE, Hansen MO, Sigsgaard T, Larsen L. Buildingrelated symptoms and molds: a two-step intervention study. Indoor Air. 2002;12(4):273-7.
113. Jarvis JQ, Morey PR. Allergic respiratory disease and fungal remediation in a building in a subtropical climate. Appl Occup Environ Hyg. 2001;16(3):380-8.
114. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141-51.
115. Kanu A, Patel K. Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in CF With Anti-IgE Antibody (Omalizumab). Pediatr Pulmonol. 2008;43:1249-51.
116. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007;62:276-7.
117. Wark PAB, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Simpson JL, McElduff P, Gibson PG. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111(5):952-7.
118. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon AU, Judson MA, Platts-Mills TAE, DeGraff AC. A randomised trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000;342:756-62.
119. Denning DW, O’Driscoll BR, Powell G, Chew F, Atherton GT, Vyas A, Miles J, Morris J, Niven RM. Randomized controlled fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med. 2009;179(1):11-8.
120. Agbetile J, Bourne M, Fairs A, Hargadon B, Desai D, Broad C, Morley J, Bradding P, Brightling CE, Green RH, Haldar P, Pashley CH, Pavord ID, Wardlaw AJ. Effectiveness of voriconazole in the treatment of Aspergillus fumigatus-associated asthma (EVITA3 study). J Allergy Clin Immunol. 2014;134(1):33-9.
121. Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther. 2002;72(4):362-9.
122. Sermet-Gaudelus I, Lesne-Hulin A, Lenoir G, Singlas E, Berche P, Hennequin C. Sputum itraconazole concentrations in cystic fibrosis patients. Antimicrob Agents Chemother. 2001;45(6):1937-8.
123. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin Pharmacokinet. 2011;50(11):689-704.
124. Pashley CH, Fairs A, Morley JP, Tailor S, Agbetile J, Bafadhel M, Brightling CE, Wardlaw AJ. Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. Med Mycol. 2012;50(4):433-8.
125. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-62.
126. Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergenspecific immunotherapy. Clin Transl Allergy. 2012;2(1):2.
127. Banerjee B, Greenberger PA, Fink JN, Kurup VP. Conformational and linear B-cell epitopes of Asp f 2, a major allergen of Aspergillus fumigatus, bind differently to immunoglobulin E antibody in the sera of allergic bronchopulmonary aspergillosis patients. Infect Immun. 1999;67(5):2284-91.
128. Twaroch TE, Focke M, Fleischmann K, Balic N, Lupinek C, Blatt K, Ferrara R, Mari A, Ebner C, Valent P, Spitzauer S, Swoboda I, Valenta R. Carrier-bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy. Clin Exp Allergy. 2012;42(6):966-75.
129. Shankar J, Singh BP, Gaur SN, Arora N. Engineered Alt a 13 fragment of Alternaria alternata abrogated IgE binding without affecting T-cell stimulation. J Clin Immunol. 2009;29(1):63-70.